<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://dtb.bmj.com">
<title>Drug and Therapeutics Bulletin current issue</title>
<link>http://dtb.bmj.com</link>
<description>Drug and Therapeutics Bulletin RSS feed -- current issue</description>
<prism:coverDisplayDate>July 2009</prism:coverDisplayDate>
<prism:publicationName>Drug and Therapeutics Bulletin</prism:publicationName>
<prism:issn>0012-6543</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://dtb.bmj.com/cgi/content/short/47/7/73?rss=1" />
  <rdf:li rdf:resource="http://dtb.bmj.com/cgi/content/short/47/7/74?rss=1" />
  <rdf:li rdf:resource="http://dtb.bmj.com/cgi/content/short/47/7/77?rss=1" />
  <rdf:li rdf:resource="http://dtb.bmj.com/cgi/content/short/47/7/81?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://www.dtb.bmj.com/icons/banner/title.gif" />
</channel>

<image rdf:about="http://www.dtb.bmj.com/icons/banner/title.gif">
<title>Drug and Therapeutics Bulletin</title>
<url>http://www.dtb.bmj.com/icons/banner/title.gif</url>
<link>http://dtb.bmj.com</link>
</image>

<item rdf:about="http://dtb.bmj.com/cgi/content/short/47/7/73?rss=1">
<title><![CDATA[Only in England]]></title>
<link>http://dtb.bmj.com/cgi/content/short/47/7/73?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2009-06-30</dc:date>
<dc:identifier>info:doi/10.1136/dtb.2009.06.0023</dc:identifier>
<dc:title><![CDATA[Only in England]]></dc:title>
<dc:publisher>British Medical Journal Publishing Group</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>73</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>73</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://dtb.bmj.com/cgi/content/short/47/7/74?rss=1">
<title><![CDATA[{blacktriangledown}Melatonin for primary insomnia?]]></title>
<link>http://dtb.bmj.com/cgi/content/short/47/7/74?rss=1</link>
<description><![CDATA[
<p>Melatonin, a hormone produced by the pineal gland, has a key role in regulating circadian rhythms, most importantly, the sleep-wake cycle.<cross-ref type="bib" refid="b1">1</cross-ref> Melatonin's action has led to its being tried as a treatment for a wide range of sleep disorders, such as jet lag, primary insomnia, sleep-wake cycle disruption and sleep problems in children with neuro-developmental disorders.<cross-ref type="bib" refid="b2">2</cross-ref><sup>&ndash;</sup><cross-ref type="bib" refid="b6">6</cross-ref> Until recently, it had not been licensed in the UK for any indication. Prolonged-release melatonin (Circadin &ndash; Lundbeck) has now been licensed as a treatment for primary insomnia. Here we consider whether this product has a place in the management of people with this condition.</p>
]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2009-06-30</dc:date>
<dc:subject><![CDATA[Paediatrics, Psychiatry, Neurology]]></dc:subject>
<dc:identifier>info:doi/10.1136/dtb.2009.06.0024</dc:identifier>
<dc:title><![CDATA[{blacktriangledown}Melatonin for primary insomnia?]]></dc:title>
<dc:publisher>British Medical Journal Publishing Group</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>77</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>74</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://dtb.bmj.com/cgi/content/short/47/7/77?rss=1">
<title><![CDATA[Which approach for first trimester miscarriage?]]></title>
<link>http://dtb.bmj.com/cgi/content/short/47/7/77?rss=1</link>
<description><![CDATA[
<p>Around 15% of all known pregnancies miscarry during the first trimester.<cross-ref type="bib" refid="b1">1</cross-ref> Historically, first trimester miscarriage was managed surgically to remove all retained products of conception, with the aim of minimising the likelihood of blood loss and infection from retained tissue.<cross-ref type="bib" refid="b2">2</cross-ref>,<cross-ref type="bib" refid="b3">3</cross-ref> Nowadays, medical management (use of drugs such as mifepristone and misoprostol) and expectant management (i.e. allowing the miscarriage to conclude naturally) have become alternatives to a surgical procedure for managing women with early miscarriage. Here, we review the evidence on these three methods to assess the benefits and disadvantages of each.</p>
]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2009-06-30</dc:date>
<dc:subject><![CDATA[Obstetrics, gynaecology and fertility, Urinary and genital tract disorders]]></dc:subject>
<dc:identifier>info:doi/10.1136/dtb.2009.06.0025</dc:identifier>
<dc:title><![CDATA[Which approach for first trimester miscarriage?]]></dc:title>
<dc:publisher>British Medical Journal Publishing Group</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>80</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>77</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

<item rdf:about="http://dtb.bmj.com/cgi/content/short/47/7/81?rss=1">
<title><![CDATA[What are excipients doing in medicinal products?]]></title>
<link>http://dtb.bmj.com/cgi/content/short/47/7/81?rss=1</link>
<description><![CDATA[
<p>Medicinal products contain not only active drugs but also other ingredients included for a variety of purposes and collectively known as excipients (from the Latin word <I>excipere</I>, meaning &lsquo;to take out or receive&rsquo;).<cross-ref type="bib" refid="b1">1</cross-ref>,<cross-ref type="bib" refid="b2">2</cross-ref> Prescribers may wrongly overlook or dismiss excipients on the assumption that these are inactive. In reality, such substances are not always inert and may have risks.<cross-ref type="bib" refid="b3">3</cross-ref> Here we consider why excipients are present in medicines, their potential unwanted effects, how they are regulated and where to find out more about them.</p>
]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2009-06-30</dc:date>
<dc:identifier>info:doi/10.1136/dtb.2009.06.0026</dc:identifier>
<dc:title><![CDATA[What are excipients doing in medicinal products?]]></dc:title>
<dc:publisher>British Medical Journal Publishing Group</dc:publisher>
<prism:number>7</prism:number>
<prism:volume>47</prism:volume>
<prism:endingPage>84</prism:endingPage>
<prism:publicationDate>2009-07-01</prism:publicationDate>
<prism:startingPage>81</prism:startingPage>
<prism:section>Articles</prism:section>
</item>

</rdf:RDF>